DHR
Danaher Corporation
$218.90
장중 · Vol 105.6K · 52주 $160.93–$242.80 · 기준 2026. 8. 21. PM 3:59 ET
일봉 $214.92 · Aug 31, 2026
DHR 가격 추세
종가
$214.92
시가
$215.10
고가
$215.38
저가
$212.59
30초 브리핑
DHR 오늘의 판단 요약
보유 데이터를 비교 가능한 문장으로 해석한 요약입니다.
52주 범위의 71%
52주 범위 중간 구간으로 가격 위치만으로 방향성은 제한적입니다.
Forward P/E 23.0배
선행 P/E가 낮아 시장은 이익 증가를 반영하고 있습니다.
20일 평균의 1.8배
평소보다 거래가 활발해 가격 움직임의 확인 강도가 높습니다.
2026-10-20
실적 전후 변동성 확대 가능성이 있으므로 컨센서스 범위와 옵션 기대변동을 함께 보세요.
펀더멘털 기준 Sep 1, 2026 · 규칙 기반 요약이며 투자 조언이 아닙니다.
핵심 통계
DHR 일봉·펀더멘털 스냅샷 기준 주요 지표
펀더멘털 스냅샷 Sep 1, 2026
Danaher Corporation designs, manufactures, and markets professional, medical, research, and industrial products and services in the United States, China, and internationally. The company operates through Biotechnology, Life Sciences, and Diagnostics segments. The Biotechnology segment provides technologies, consumables, services, and solutions that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, and aseptic fill finish; single-use hardware, consumables, and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services for diagnostic and assay development; and healthcare filtration solutions. The Life Sciences segment provides mass spectrometers; bioanalytical measurement systems; flow cytometry, genomics, lab automation, centrifugation, liquid handling automation instruments, antibodies and reagents, and particle counting and characterization; genome sample preparation; microscopes; protein consumables; filtration products; and genomic medicines, such as custom nucleic acid products, and plasmid DNA, RNA, and proteins under the ABCAM, ALDEVRON, BECKMAN COULTER, GENEDATA, IDT, LEICA MICROSYSTEMS, MOLECULAR DEVICES, PALL, PHENOMENEX, and SCIEX brands. The Diagnostics segment offers clinical instruments, consumables, software, and services that hospitals, physicians' offices, reference laboratories and other critical care settings use to diagnose disease and make treatment decisions. The company was formerly known as Diversified Mortgage Investors, Inc. and changed its name to Danaher Corporation in 1984. Danaher Corporation was incorporated in 1969 and is headquartered in Washington, the District Of Columbia.
2200 Pennsylvania Avenue N.W. · Washington, DC, United States · 직원 58,000명
시가총액
$150.13B
Trailing P/E
38.5
최근 12개월 이익 기준
Forward P/E
23.0
이익 증가 기대 반영
EPS (TTM)
$5.62
배당 수익률
0.74%
배당성향
25.7%
베타
0.80
시장보다 방어적
ROE
7.6%
P/B
2.85
EV/EBITDA
21.9
52주 범위
$160.93 – $242.80
현재 위치 71%
거래량
4.00M
20일 평균 2.28M · 1.8배
애널리스트 의견
매수 85%
총 26명 · 0m
DITM LEAPS Analysis
DHR 장기 DITM 콜옵션을 진입 적합도 순으로 비교
| Contract | Expiry | Strike | Price | Lev. | Delta | Extrinsic | Spread | IV | OI | Score | 상세 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DHR280121C00120000 | 1/21/28 · 1.4Y | $120.00 | $102.00 | 1.9x | 0.9137 | 8.3% | 2.94% | 50.96% | 6 | 81.60 | |
| DHR280121C00115000 | 1/21/28 · 1.4Y | $115.00 | $107.55 | 1.8x | 0.9154 | 8.4% | 3.25% | 55.08% | 1 | 79.06 | |
| DHR280121C00125000 | 1/21/28 · 1.4Y | $125.00 | $98.00 | 2.0x | 0.9042 | 9.6% | 3.06% | 50.29% | 1 | 78.16 | |
| DHR280121C00130000 | 1/21/28 · 1.4Y | $130.00 | $95.00 | 2.0x | 0.8899 | 12.0% | 3.58% | 51.38% | 1 | 75.00 | |
| DHR280121C00140000 | 1/21/28 · 1.4Y | $140.00 | $86.00 | 2.1x | 0.8659 | 14.5% | 4.65% | 50.97% | 8 | 73.08 | |
| DHR280121C00145000 | 1/21/28 · 1.4Y | $145.00 | $82.00 | 2.2x | 0.8554 | 16.4% | 4.88% | 49.76% | 14 | 71.80 | |
| DHR280121C00150000 | 1/21/28 · 1.4Y | $150.00 | $78.10 | 2.3x | 0.8455 | 18.6% | 4.10% | 48.06% | 13 | 70.25 | |
| DHR280121C00155000 | 1/21/28 · 1.4Y | $155.00 | $74.25 | 2.4x | 0.8331 | 21.1% | 4.71% | 47.22% | 36 | 68.82 | |
| DHR280121C00160000 | 1/21/28 · 1.4Y | $160.00 | $70.50 | 2.5x | 0.8198 | 24.0% | 5.67% | 46.57% | 15 | 65.09 | |
| DHR280121C00165000 | 1/21/28 · 1.4Y | $165.00 | $67.05 | 2.6x | 0.8071 | 27.6% | 4.62% | 45.31% | 102 | 64.69 | |
| DHR280121C00170000 | 1/21/28 · 1.4Y | $170.00 | $63.70 | 2.7x | 0.7926 | 31.6% | 4.71% | 44.64% | 7 | 58.83 | |
| DHR280121C00175000 | 1/21/28 · 1.4Y | $175.00 | $60.40 | 2.8x | 0.7777 | 36.2% | 4.64% | 43.88% | 38 | 57.16 | |
| DHR280121C00180000 | 1/21/28 · 1.4Y | $180.00 | $57.20 | 2.8x | 0.7615 | 41.3% | 5.94% | 43.64% | 63 | 53.37 |
재무제표
DHR 연간 손익·현금흐름·재무상태
매출 성장률
+2.9%
최근 연간 YoY
EPS 성장률
-4.5%
최근 연간 YoY
영업이익률
19.1%
최근 연간
FCF 마진
21.4%
잉여현금흐름 / 매출
매출 추세
순이익 추세
잉여현금흐름 추세
| 항목 | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| 매출 | $24.57B+2.9% | $23.88B-0.1% | $23.89B-10.3% | $26.64B |
| 매출총이익 | $14.52B+2.2% | $14.21B+1.2% | $14.03B-13.3% | $16.19B |
| 영업이익 | $4.69B-3.6% | $4.86B-6.5% | $5.20B-31.0% | $7.54B |
| 순이익 | $3.61B-7.3% | $3.90B-18.2% | $4.76B-33.9% | $7.21B |
| 희석 EPS | $5.05-4.5% | $5.29-17.1% | $6.38-34.0% | $9.66 |
| EBITDA | $6.95B-4.5% | $7.28B-2.9% | $7.50B-20.9% | $9.48B |
| 영업현금흐름 | $6.42B-4.1% | $6.69B-6.6% | $7.16B-15.9% | $8.52B |
| 잉여현금흐름 | $5.26B-0.7% | $5.30B-8.4% | $5.78B-21.9% | $7.40B |
| 총자산 | $83.46B+7.6% | $77.54B-8.2% | $84.49B+0.2% | $84.35B |
| 총부채 | $19.70B+14.9% | $17.15B-12.2% | $19.54B-5.2% | $20.62B |
최신 연도 우선 · 작은 퍼센트는 직전 연도 대비 변화입니다.
캘린더
DHR 실적·배당 일정
매출 하단
$6.51B
EPS 하단
$1.89
매출 상단
$6.67B
배당 지급일
2026-07-31
32일 전
실적 발표일
2026-10-20
D-49
EPS 상단
$1.99
매출 컨센서스
$6.56B
EPS 컨센서스
$1.92
배당락일
2026-06-26
67일 전
최근 배당
| 배당락일 | 주당 배당 |
|---|---|
| Jun 26, 2026 | $0.4000 |
| Mar 27, 2026 | $0.4000 |
| Dec 26, 2025 | $0.3200 |
| Sep 26, 2025 | $0.3200 |
| Jun 27, 2025 | $0.3200 |
| Mar 28, 2025 | $0.3200 |
| Dec 27, 2024 | $0.2700 |
| Sep 27, 2024 | $0.2700 |
뉴스
DHR 관련 최신 기사
일반Is Danaher Stock Underperforming the Nasdaq?
Danaher has underperformed the Nasdaq over the past year, but analysts are highly optimistic about the stock’s prospects.
Barchart · Aug 31, 2026
일반Jim Cramer Calls BillionToOne (BLLN) a “Pretty Darn Good Company”
When a caller asked for the Mad Money host’s take on BillionToOne, Inc. (NASDAQ:BLLN) during the lightning round on August 26, Jim Cramer commented: You know, we did a big piece on this, and we decided, you know, it’s a pretty darn good company. I know it’s expensive, but you know what? Look, genetic diagnostic, […]
Insider Monkey · Aug 28, 2026
제품·기술Why Danaher (DHR) Remains a Healthcare Compounder to Watch
Aristotle Capital Management, LLC, an investment management company, released its “Value Equity Fund” Q2 2026 investor letter. A copy of the letter can be downloaded here. The Fund delivered a 4.32% total return in Q2 2026, underperforming the 13.87% gain for the Russell 1000 Value Index and the 15.20% return for the S&P 500, while […]
Insider Monkey · Aug 28, 2026
실적Why Is Avantor (AVTR) Up 5.4% Since Last Earnings Report?
Avantor (AVTR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks · Aug 28, 2026
실적1 Profitable Stock on Our Buy List and 2 We Brush Off
Even if a company is profitable, it doesn’t always mean it’s a great investment. Some struggle to maintain growth, face looming threats, or fail to reinvest wisely, limiting their future potential.
StockStory · Aug 28, 2026
- 일반
3 Industrials Stocks with Questionable Fundamentals
Even if they go mostly unnoticed, industrial businesses are the backbone of our country. But they are at the whim of volatile macroeconomic factors that influence capital spending (like interest rates), and the market seems convinced that demand will slow. Due to this bearish outlook, the industry has tumbled by 2.5% over the past six months. This performance is a far cry from the S&P 500’s 10.8% ascent.
StockStory · Aug 26, 2026
제품·기술Danaher Rides on Strength in Biotechnology Segment: Will It Sustain?
DHR's Biotechnology segment grows as China demand, bioprocessing and improving discovery markets offset regional headwinds.
Zacks · Aug 25, 2026
일반Cancer Vaccine Breakthrough Lifts 5 Biotech Names. Here’s Who’s Best Positioned.
Merck and Moderna just proved their cancer vaccine works, and the ripple effects reach far beyond either company. Five names stand to collect a toll on every single dose manufactured, but not all of them carry the same risk.
24/7 Wall St. · Aug 25, 2026
- 일반
Qiagen names Jonathan Pratt as CEO amid takeover talks
Investing.com -- Qiagen N.V. (NYSE:QGEN) announced Monday that Jonathan M. Pratt will become chief executive officer on September 1, 2026, as the molecular testing company continues discussions with potential buyers.
Investing.com · Aug 24, 2026
- 일반
Here's What Is Shaping Abbott's Diagnostics Growth
ABT's Diagnostics growth is being reshaped as weaker respiratory testing offsets healthy routine demand and 13% cancer diagnostics growth.
Zacks · Aug 24, 2026
홀더
DHR 내부자·기관 보유 현황
최신 보고 목록 기준이며 실제 거래 시점과 보고일 사이에는 시차가 있습니다.
기관 보유
84.5%
기관 보유 (유동주식)
94.9%
내부자 보유
11.0%
기관 수
2,868
주요 기관 홀더
| 홀더 | 주식 수 | 평가액 | 지분 | 변동 | 보고일 |
|---|---|---|---|---|---|
| Blackrock Inc. | 55.08M | $11.76B | 7.8% | 6.7% | Jun 30, 2026 |
| Vanguard Capital Management LLC | 41.38M | $8.84B | 5.9% | 0.6% | Jun 30, 2026 |
| FMR, LLC | 29.54M | $6.31B | 4.2% | 31.1% | Jun 30, 2026 |
| State Street Corporation | 28.46M | $6.08B | 4.0% | 2.0% | Jun 30, 2026 |
| Wellington Management Group, LLP | 16.32M | $3.48B | 2.3% | 10.4% | Jun 30, 2026 |
| Capital International Investors | 15.50M | $3.31B | 2.2% | 10.6% | Jun 30, 2026 |
| Geode Capital Management, LLC | 14.28M | $3.05B | 2.0% | 0.9% | Jun 30, 2026 |
| Vanguard Portfolio Management LLC | 14.21M | $3.03B | 2.0% | 1.8% | Jun 30, 2026 |
| JPMORGAN CHASE & CO | 12.19M | $2.60B | 1.7% | -28.0% | Jun 30, 2026 |
| Price (T.Rowe) Associates Inc | 11.45M | $2.45B | 1.6% | -25.4% | Jun 30, 2026 |
면책조항: 증시가격은 모든 주식 시장의 최신 증시가격을 표시하는 것은 아니며, 정보가 지연되거나 잘못될 수 있습니다. 거래 목적이나 조언이 아닌 정보 제공 목적으로만 제공됩니다.